Despite the well-established role of NF-κB signaling in lymphoma pathogenesis and treatment resistance, conflicting results on the prognostic significance of NF-κB and RelA/p65 expression (as a surrogate marker of NF-κB activation) in DLBCL have been reported by previous clinical studies [8, 9, 34-36]. Here, NFKB1 is linked to lymphoma.